Related Experiment Video
Updated: May 5, 2026
08:19
Hollow Microneedle-based Sensor for Multiplexed Transdermal Electrochemical Sensing
Published on: June 1, 2012
14.5K
Electro-responsive paper patch for enhanced transdermal methotrexate delivery in psoriasis treatment
Elham Momtaz1, Masoud A Mehrgardi1
1Department of Chemistry, University of Isfahan 81746-73441 Isfahan, Iran.
International Journal of Pharmaceutics
|August 24, 2025
Summary
A novel paper-based iontophoretic patch effectively delivers methotrexate (MTX) through psoriatic skin. This wearable device offers a patient-friendly approach for managing psoriasis with minimal systemic toxicity.
Area of Science:
- Biomedical Engineering
- Materials Science
- Dermatology
Background:
- Transdermal drug delivery of high-molecular-weight drugs like methotrexate (MTX) is challenging in psoriatic skin.
- Psoriasis treatment often requires effective and localized drug delivery methods.
Purpose of the Study:
- To develop a wearable iontophoretic patch for enhanced transdermal delivery of MTX.
- To evaluate the efficacy and safety of the MTX-loaded patch in a psoriasis mouse model.
Main Methods:
- Fabrication of a polypyrrole-coated paper substrate for MTX loading and controlled release.
- Application of a -1.2 V potential for iontophoretic drug delivery.
- Assessment of MTX permeation through skin models.
- Evaluation of therapeutic efficacy and systemic toxicity in an imiquimod (IMQ)-induced psoriasis mouse model.
Main Results:
- The iontophoretic patch achieved efficient MTX release and permeation (20.8 ± 0.4 μg/cm² over 2 h) with minimized passive leakage.
- The patch significantly alleviated psoriasis symptoms in the mouse model.
- Histological analysis confirmed therapeutic efficacy and good biocompatibility, with low systemic toxicity.
Conclusions:
- The developed paper-based iontophoretic platform is a promising strategy for precise and patient-friendly management of psoriasis.
- This technology offers potential for treating other dermatological disorders requiring transdermal drug delivery.
Related Concept Videos
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:29Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
177
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
177
01:18Transdermal Drug Delivery Systems
233
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
233